The pharmaceutical firm issued a formal statement under Section 401(d) of the NYSE American Company Guide after regulators flagged the irregular market behavior. While corporate policy typically dictates silence regarding short-term fluctuations, the exchange mandated a disclosure to address investor concerns. Management urged shareholders to ignore speculative noise and rely strictly on official filings submitted to the U.S. Securities and Exchange Commission.

China Pharma Holdings operates a specialized business model centered on cardiovascular, CNS, infectious, and digestive diseases. Supported by eight GMP-certified production lines and a nationwide distribution network, the company maintains its primary subsidiary, Hainan Helpson Medical & Biotechnology, in Haikou City. Despite the recent volatility, leadership provided no guidance on potential external factors currently influencing the stock's performance.